Trial Profile
Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG, a Positron Emission Tomography Tracer for Imaging the Activation of the Immune System in Healthy Humans
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 May 2018
Price :
$35
*
At a glance
- Drugs 18F-F-AraG (Primary)
- Indications Cancer
- Focus Diagnostic use
- Sponsors CellSight Technologies
- 14 May 2018 Status changed from recruiting to completed.
- 01 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 07 Jan 2015 New trial record